Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Depreciation & Amortization - Total (2017 - 2025)

Historic Depreciation & Amortization - Total for Vanda Pharmaceuticals (VNDA) over the last 9 years, with Q3 2025 value amounting to $301000.0.

  • Vanda Pharmaceuticals' Depreciation & Amortization - Total rose 3935.19% to $301000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year increase of 2586.0%. This contributed to the annual value of $900000.0 for FY2024, which is 217.39% down from last year.
  • Vanda Pharmaceuticals' Depreciation & Amortization - Total amounted to $301000.0 in Q3 2025, which was up 3935.19% from $267000.0 recorded in Q2 2025.
  • In the past 5 years, Vanda Pharmaceuticals' Depreciation & Amortization - Total registered a high of $374000.0 during Q4 2021, and its lowest value of $200000.0 during Q3 2023.
  • Its 5-year average for Depreciation & Amortization - Total is $275578.9, with a median of $284000.0 in 2022.
  • In the last 5 years, Vanda Pharmaceuticals' Depreciation & Amortization - Total crashed by 3311.04% in 2023 and then surged by 3935.19% in 2025.
  • Quarter analysis of 5 years shows Vanda Pharmaceuticals' Depreciation & Amortization - Total stood at $374000.0 in 2021, then dropped by 24.06% to $284000.0 in 2022, then decreased by 27.82% to $205000.0 in 2023, then rose by 27.8% to $262000.0 in 2024, then increased by 14.89% to $301000.0 in 2025.
  • Its last three reported values are $301000.0 in Q3 2025, $267000.0 for Q2 2025, and $231000.0 during Q1 2025.